Monitoring intestinal microbiota profile: A promising method for the ultraearly detection of colorectal cancer

Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
Medical Hypotheses (Impact Factor: 1.07). 02/2011; 76(5):670-2. DOI: 10.1016/j.mehy.2011.01.028
Source: PubMed


Colorectal cancer is one of the most common cancers and is very hard to be detected at an ultraearly stage because of lack of valuable predicating methods that often lead to treatment failure. Intestinal microbiota has long been considered to implicate in colorectal cancer pathology; and many recent reports point out a close linkage between the intestinal bacteria and the genesis of the tumor. Present studies indicate that the structure and characteristics of the intestinal microbiota are significantly altered in colorectal cancer, precancerous lesion, and high risk population compared with healthy controls and low risk population. Based on the current studies and theories, we postulate monitoring the intestinal bacterial profile by the molecular methods that could fulfill the ultraearly prediction about the degree of the risk developing into colorectal cancer. Further population-based epidemiological study is useful to reveal the characteristics of the intestinal microbiota in ultraearly colorectal cancer, which might provide some novel prophylactic and therapeutic strategies for the colorectal cancer.

6 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mucosal surfaces of the gut are colonized by large numbers of heterogeneous bacteria that contribute to intestinal health and disease. In genetically susceptible individuals, a 'pathogenic community' may arise, whereby abnormal gut flora contributes to alterations in the mucosa and local immune system leading to gastrointestinal disease. These diseases include enteric infections, such as Clostridium difficile infection, small intestinal bacterial overgrowth, functional gastrointestinal disorders (including IBS), IBD and colorectal cancer. Prebiotics, probiotics and synbiotics (a combination of prebiotics and probiotics) have the capacity to reverse pathologic changes in gut flora and local immunity. Intestinal health and disease need to be thoroughly characterized to understand the interplay between the indigenous microbiota, the immune system and genetic host factors. This Review provides a broad overview of the importance of the intestinal microbiota in chronic disorders of the gut.
    Nature Reviews Gastroenterology &#38 Hepatology 08/2011; 8(9):523-31. DOI:10.1038/nrgastro.2011.133 · 12.61 Impact Factor
  • Source
    Building Babies: Primate Development in Proximate and Ultimate Perspective, Edited by KBH Clancy, J Rutherford, K Hinde, 06/2013: chapter Infant gut microbiota: developmental influences and health outcomes: pages 233-256; Springer.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancers of the gastrointestinal (GI) tract continue to represent a major health problem, despite progress in therapy. Gut microbiota is a key element related to the genesis of GI cancers, countless papers addressing this burning issue across the world. We provide an updated knowledge of the involvement of gut microbiota in GI tumorigenesis, including its underlying mechanisms. We present also a comprehensive review of the evidence from animal and clinical studies using probiotics and/or prebiotics in the prevention and/or therapy of GI tumours, of GI cancer therapy-related toxicity and of post-operative complications. We summarize the anticarcinogenic mechanisms of these biotherapeutics from in vitro, animal and clinical interventions. More research is required to reveal the interactions of microflora with genetic, epigenetic and immunologic factors, diet and age, before any firm conclusion be drawn. Well-designed, randomized, double blind, placebo-controlled human studies using probiotics and/or prebiotics, with adequate follow-up are necessary in order to formulate directions for prevention and therapy.
    Cancer letters 08/2013; 345(2). DOI:10.1016/j.canlet.2013.08.013 · 5.62 Impact Factor
Show more